Protein Brewery Raises $20.5M Amidst US Regulatory Review

The Protein Brewery, a Dutch innovator in mycoprotein production, has successfully closed an €18 million ($20.5 million) Series B extension, demonstrating strong investor confidence despite a recent advisory from the U.S. Food and Drug Administration (FDA). The funding round was spearheaded by ABN AMRO Sustainable Impact Fund, with significant participation from existing backers including Invest-NL, Novo Holdings, Madeli, and the Brabant Development Agency (BOM).

This capital infusion is earmarked for substantial expansion of the company's production capabilities at its Netherlands facility, aiming to reach over 2,000 tons annually. The funds will also fuel market entry into Europe in the third quarter, support new clinical research into the health attributes of its proprietary ingredient, and facilitate regulatory submissions in key international markets such as Canada, Australia, New Zealand, and India. The company recently achieved a significant milestone with regulatory clearance for its novel mycelium ingredient in the European Union.

The U.S. regulatory path encountered a temporary obstacle when the FDA recommended the withdrawal of The Protein Brewery's Generally Recognized as Safe (GRAS) notice. The agency cited deficiencies in the submitted application, including issues with animal study design, insufficient safety data for proposed consumption levels, and inadequate characterization of the ingredient's composition and secondary metabolites. While the FDA advised ceasing evaluation, CEO Thijs Bosch characterizes this as a manageable setback, emphasizing that no fundamental re-testing of their core science is required.

Bosch indicated that the company plans to revise and resubmit its GRAS application, aligning the data presentation with the rigorous standards met for European regulatory approval. He expressed optimism that a pre-submission meeting with the FDA in the coming weeks will address all concerns, leading to a resubmission and a potential "no further questions" letter by the first quarter of 2027. In the interim, the company is enhancing its self-affirmed GRAS documentation to empower U.S. customers to utilize its ingredients with confidence, anticipating initial product launches in the U.S. market by late 2026.

The Protein Brewery's core offering, Fermotein, a mycoprotein powder derived from biomass fermentation using the *Rhizomucor pusillus* mycelium strain, is gaining traction, particularly within the active and sports nutrition sectors. The ingredient is lauded for its rich protein content, fiber, and micronutrients, with a strategic focus on the healthy aging demographic. The company is actively pursuing human clinical studies, including a significant trial scheduled for early 2027 with Wageningen University, to further validate its health benefits.

A key competitive advantage for The Protein Brewery lies in its production process. The company utilizes non-sterile fermentation, which structurally reduces both capital expenditure and operational costs compared to conventional biotech fermentation methods. This cost efficiency is projected to improve significantly as production scales, with plans to supply 600 metric tons in 2027 and exceed 2,000 tons by 2029. Bosch highlighted the robustness of their strain, which avoids mycotoxin production and thrives under conditions of high temperature and low pH, simplifying downstream processing and enabling more cost-effective scaling. This contrasts with strains like *Fusarium*, used by competitors such as Quorn, and positions The Protein Brewery favorably in the rapidly expanding alternative protein market, which is projected for substantial growth driven by increasing consumer demand for sustainable and nutritious food sources.